ARCHIVES

Survivors With Gene Variant At More Risk For Heart Disease

This article is from The Cancer Letter archive.

Vol. 33 No. 6 | June 25, 2010

Download PDF Visit The Full Archive

Related Articles

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

December 2, 1983

In Brief: CREG To Be Used In Viral Oncology, Nutrition, Cell Kinetics, Immunology, Rauscher Tells NCAB

April 4, 1975

First Clinical Guidelines On Ductal Lavage Published

March 29, 2002

NCI Advisory Group, Other Cancer Meetings

August 16, 1985

TTF Increased Survival Compared To Chemotherapy

December 31, 2010

Pharmacogenomics May Lead To Individualized Treatment

June 25, 2004